Ischemic heart disease is the leading cause of death in developed countries and a major cause of hospital admissions. In the U.S. 5.7 million people are living with heart failure and 670,000 new cases will be diagnosed each year [1].  Ischemic heart disease is often treated with medication, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). However, for many patients these treatments carry risk or may be ineffective. It is crucial that new treatment alternatives are developed to treat this massive need.

PACE has been shown to improve microcirculation and reduce the inflammation time associated with healing. PACE may offer a non-invasive, highly effective treatment option for patients with ischemic heart disease.

References

1. American Heart Disease Association.

The indications described above are not approved by the FDA in the U.S. This information is being provided as educational guidance upon which to base future studies.